Trial Profile
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Nerinetide (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ESCAPE-NA1
- Sponsors NoNO
- 23 Jan 2024 Results (n=77) of analysis assessing infarct evolution on MR-DWI after thrombectomy in patients included had MRI of sufficient quality published in the Neurology
- 01 Sep 2023 Results assessing whether CTP modifies the effect of near-complete reperfusion on clinical outcomes, ie, whether poor clinical outcomes despite near-complete reperfusion can be partly or fully explained by CTP findings published in the American Journal of Neuroradiology
- 12 Apr 2023 Results (n=1092) assessing the incidence of Infarct in a new territory, outcomes after Infarct in a new territory, and the impact of concurrent treatments with intravenous thrombolysis and nerinetide, published in the Stroke.